StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$17.27−0.82 (-4.53%)

Close on Nov 16, 2026Market cap $3.78BP/E –Yield –

Relay Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Relay Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $279.60M, up 2.0% year over year. For fiscal 2025 it was $261.38M, down 18.1% from the year before. The highest annual figure on record is $330.02M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$261.38M-18.1%
FY2024Dec 31, 2024$319.09M-3.3%
FY2023Dec 31, 2023$330.02M+34.0%
FY2022Dec 31, 2022$246.36M+42.7%
FY2021Dec 31, 2021$172.65M+72.9%
FY2020Dec 31, 2020$99.86M+42.0%
FY2019Dec 31, 2019$70.31M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$77.14M+13.0%
Q2 FY2026Jun 30, 2026$76.48M+19.7%
Q1 FY2026Mar 31, 2026$70.56M-4.4%
Q4 FY2025Dec 31, 2025$55.42M-18.6%
Q3 FY2025Sep 30, 2025$68.26M-10.9%
Q2 FY2025Jun 30, 2025$63.90M-30.5%
Q1 FY2025Mar 31, 2025$73.81M-10.4%
Q4 FY2024Dec 31, 2024$68.08M-12.2%
Q3 FY2024Sep 30, 2024$76.62M-6.0%
Q2 FY2024Jun 30, 2024$91.99M+4.3%
Q1 FY2024Mar 31, 2024$82.40M-0.5%
Q4 FY2023Dec 31, 2023$77.50M+15.2%
Q3 FY2023Sep 30, 2023$81.49M+21.8%
Q2 FY2023Jun 30, 2023$88.20M+45.8%
Q1 FY2023Mar 31, 2023$82.83M+60.3%
Q4 FY2022Dec 31, 2022$67.28M+29.6%
Q3 FY2022Sep 30, 2022$66.90M+48.8%
Q2 FY2022Jun 30, 2022$60.51M+34.0%
Q1 FY2022Mar 31, 2022$51.67M+68.7%
Q4 FY2021Dec 31, 2021$51.91M+61.6%
Q3 FY2021Sep 30, 2021$44.97M+84.5%
Q2 FY2021Jun 30, 2021$45.15M+108.4%
Q1 FY2021Mar 31, 2021$30.62M+41.1%
Q4 FY2020Dec 31, 2020$32.12M+43.4%
Q3 FY2020Sep 30, 2020$24.38M+33.5%
Q2 FY2020Jun 30, 2020$21.67M+32.1%
Q1 FY2020Mar 31, 2020$21.70M–
Q4 FY2019Dec 31, 2019$22.41M–
Q3 FY2019Sep 30, 2019$18.26M–
Q2 FY2019Jun 30, 2019$16.40M–

More Relay Therapeutics figures

See a number that looks wrong?